Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Pfizer CDR CAD Hedged | NEO:PFE | NEO | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -0.34% | 11.56 | 11.56 | 11.60 | 11.60 | 11.51 | 11.57 | 21,678 | 17:27:34 |
From Nov 2019 to Nov 2024
Hot Features
Premium
By Tess Stynes
Pfizer Inc. (PFE) said the U.S. Food and Drug Administration will take three months more than initially expected to review the pharmaceutical company's application to market a new treatment for rheumatoid arthritis.
The FDA now is aiming for a decision by Nov. 21.
The extension of the review period beyond an initially targeted Aug. 21 decision date had been anticipated so the FDA could look at additional data analyses that it had requested.
In May, an FDA advisory committee voted 8-2 to recommend agency approval of tofacitinib.
Pfizer and other major drug makers have been aiming to add new products to replace former top sellers as the industry copes with a patent cliff.
Pfizer in July reported that its second-quarter earnings rose 25% on lower expenses as the company continued to see sales of former anticholesterol blockbuster Lipitor slide amid competition from generic versions.
Shares were down by a penny at $23.90 in recent premarket trading.
Write to Tess Stynes at Tess.Stynes@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Pfizer CDR CAD Hedged Chart |
1 Month Pfizer CDR CAD Hedged Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
